Adverum Biotechnologies (ADVM) Prices 9.5M Share Common Offering at $13.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Adverum Biotechnologies (ADVM) Ramps 17% Despite Pending Stock Offering
February 11, 2020 10:50 AM ESTAdverum Biotechnologies (NASDAQ: ADVM) gains 17% despite pending $100M stock offering
... MoreAdverum Biotechnologies (ADVM) PT Raised to $13 at SunTrust
February 11, 2020 7:22 AM ESTSunTrust analyst Joon Lee raised the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $13.00 (from $8.00) while maintaining a Hold rating.... More
Adverum Biotechnologies (ADVM) to Offer $100M in Stock
February 10, 2020 4:02 PM ESTAdverum Biotechnologies, Inc. (Nasdaq: ADVM) announced that it has commenced an underwritten public offering of $100 million of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common... More
UPDATE: Chardan Capital Markets Upgrades Adverum Biotechnologies (ADVM) to Buy
February 10, 2020 9:54 AM EST(Updated - February 10, 2020 9:55 AM EST)
Chardan Capital Markets analyst Gbola Amusa upgraded Adverum Biotechnologies (NASDAQ: ADVM) from Neutral to Buy with a price target of $20.00.
The analyst commented, "In a population of patients with frequent anti-VEGF injections at baseline, Adverum, with combined Cohort 1 and 2 data, has shown 10/12 (83%)... More
Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)
February 10, 2020 9:21 AM ESTToday's Pre-Open Stock Movers
vTv Therapeutics Inc. (Nasdaq: VTVT) 79.5% HIGHER; announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D). TTP399 is a novel, liver-selective glucokinase activator taken once a day. The 12-week trial investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 people with type 1 diabetes on optimized insulin therapy. The study was conducted with support from JDRF International (JDRF), the leading provider of T1D research funding... More
Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
February 10, 2020 5:57 AM ESTAdverum Biotechnologies, Inc. (NASDAQ: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from the OPTIC Phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy. OPTIC includes treatment-experienced patients with wet age-related macular degeneration (AMD). The data are being presented today by David S. Boyer, M.D., senior partner, Retina-Vitreous... More
